Trial · NCT07493161
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
NCT07493161, Not applicable, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL. Trials, record NCT07493161. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07493161
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL
- NCT number
- NCT07493161
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 110 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- Ph+ ALL
- Interventions
- Olverembatinib, Venetoclax, Blinatumomab, Chemotherapy Backbone Regimens, Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT), Inotuzumab ozogamicin
- First posted
- 2026-03-25
- Last updated
- 2026-07-23
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of BCR::ABL1 ≤0.01% at 90 days (after three cycles of treatment) | up to 90 days | |
| Primary | Modified Event-Free Survival (mEFS) from start of InO consolidation | From the start of InO consolidation therapy up to 2 years | |
| Secondary | Overall Survival | up to 5 years | |
| Secondary | Relapse-Free Survival | up to 5 years | |
| Secondary | Cumulative incidence of molecular relapse | up to 5 years | |
| Secondary | Cumulative incidence of hematologic relapse | up to 5 years | |
| Secondary | Proportion of patients with next-generation sequencing minimal residual disease <0.01% after three cycles of treatment (90 days) | up to 90 days | |
| Secondary | Proportion of patients with next-generation sequencing minimal residual disease <0.01% at the end of consolidation therapy | up to 1 year | |
| Secondary | Incidence of treatment-related cardiovascular events | up to 5 years from the initiation of treatment | |
| Secondary | Proportion of patients with BCR::ABL1 ≤0.01% at completion of consolidation therapy | up to 9 months |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07493161
GET https://conductscience.org/api/trials/v1/NCT07493161/registered